Registration opens 04/12/2018
This event is no longer available for registration.
Protein turnover is crucial in maintaining cellular homeostasis and this process is largely controlled by the Ubiquitin Proteasome Pathway (UPP). The pathway consists of an enzymatic cascade that links the polypeptide cofactor Ubiquitin to specific protein targets, which mark them for degradation by the proteasome. This cascade is highly regulated and impacts virtually all cellular processes including cell cycle progression, cell proliferation, cell differentiation and apoptosis. Malfunction of the UPP has been implicated in the development of diseases such as cancer, immune disorders and neurodegeneration.
The ability to understand and manipulate the UPP is a major objective in being able to manage disease biology. While the validity of this approach was first exemplified by the proteasome inhibitor bortezomib, approved by the FDA in 2003 and used in the treatment of multiple myeloma and mantle cell lymphoma, subsequent advances in understanding the role of different components in the UPP have allowed the development of other high quality chemical probes and inhibitors.
This meeting aims to showcase recent innovations by scientists working in both academia and industry in this exciting and rapidly expanding field.
It is targeted at academic and industrial scientists engaged in all aspects of research into the ubiquitin proteasome pathway and those interested in broadening their knowledge in this rapidly expanding field.
14/15 Belgrave Square
Tel: +44 (0)20 7598 1561
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
For booking terms and conditions click here.
SCI Members attending this meeting are able to claim CPD points.
An abstract of maximum one A4 page or 300 words, indicating title, authors and preference for presentation option (15 or 30 minute oral, or poster) should be sent to firstname.lastname@example.org by Friday 12 April 2019 with the subject line "TUPP 2019 – abstract submission". Subjects for presentation can include results, reviews or plans and may have already been presented elsewhere. Naturally, there are limited oral presentation slots and these will be allocated to achieve a balanced programme.
An exhibition will take place alongside the conference for companies and related organisations who may wish to exhibit. Please email email@example.com for further information and prices. Spaces are limited and will be allocated on a first-come, first-served basis.
Become an SCI Member to receive benefits and discounts